Rockefeller Capital Management’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.04K Sell
375
-418
-53% -$3.06K ﹤0.01% 4340
2026
Q1
$5.07K Buy
793
+634
+399% +$4.09K ﹤0.01% 4238
2025
Q4
$946 Buy
+159
New +$844 ﹤0.01% 4453
2023
Q1
– Sell
-14
Closed – – 3327
2022
Q4
$0 Sell
14
-261
-95% -$901 ﹤0.01% 4121
2022
Q3
$0 Hold
275
– – ﹤0.01% 4258
2022
Q2
$0 Hold
275
– – ﹤0.01% 4321
2022
Q1
$0 Hold
275
– – ﹤0.01% 4021
2021
Q4
$0 Sell
275
-1,048
-79% -$4.55K ﹤0.01% 3937
2021
Q3
$9K Sell
1,323
-55,779
-98% -$418K ﹤0.01% 2941
2021
Q2
$524K Buy
+57,102
New +$579K ﹤0.01% 1179
2020
Q4
– Sell
-157
Closed -$1K – 2975
2020
Q3
$1K Buy
157
+58
+59% +$591 ﹤0.01% 2519
2020
Q2
$1K Sell
99
-64
-39% -$662 ﹤0.01% 2485
2020
Q1
$1K Buy
+163
New +$1.58K ﹤0.01% 2300
2019
Q4
– Sell
-4,900
Closed -$53K – 2168
2019
Q3
$53K Buy
4,900
+100
+2% +$1.08K ﹤0.01% 951
2019
Q2
$61K Hold
4,800
– – ﹤0.01% 782
2019
Q1
$186K Hold
4,800
– – ﹤0.01% 625
2018
Q4
$98K Buy
+4,800
New +$144K ﹤0.01% 459

Other funds holding PBYI

Rockefeller Capital Management's PBYI Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Puma Biotechnology (PBYI) stake by 53% in Q2 2026, selling an estimated $3.06K and leaving 375 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4340.

Rockefeller Capital Management first reported a position in PBYI in Q4 2018 and has held it in 17 quarters since. The position peaked at $524K in Q2 2021. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Rockefeller Capital Management held 375 shares of Puma Biotechnology worth $3.04K as of Q2 2026.
  • Rockefeller Capital Management sold 418 Puma Biotechnology shares in Q2 2026, an estimated $3.06K.
  • Puma Biotechnology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4340 holding.
  • Rockefeller Capital Management first reported a position in Puma Biotechnology in Q4 2018 and has held it in 17 quarters since.
  • Rockefeller Capital Management's Puma Biotechnology position peaked at $524K in Q2 2021.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.